[go: up one dir, main page]

ES2108298T3 - 4-estrenos puenteados en 19,11, activos como gestagenos. - Google Patents

4-estrenos puenteados en 19,11, activos como gestagenos.

Info

Publication number
ES2108298T3
ES2108298T3 ES93922949T ES93922949T ES2108298T3 ES 2108298 T3 ES2108298 T3 ES 2108298T3 ES 93922949 T ES93922949 T ES 93922949T ES 93922949 T ES93922949 T ES 93922949T ES 2108298 T3 ES2108298 T3 ES 2108298T3
Authority
ES
Spain
Prior art keywords
bridged
premieres
gestagens
active
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93922949T
Other languages
English (en)
Inventor
Eckhard Ottow
Wolfgang Schwede
Wolfgang Halfbrodt
Karl-Heinrich Fritzemeier
Rolf Krattenmacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2108298T3 publication Critical patent/ES2108298T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Toys (AREA)
  • Eye Examination Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Glass Compositions (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)

Abstract

EN LA PRESENTE INVENCION SE DESCRIBEN LOS NUEVOS 4 - ESTRENO PUENTEADOS 19,11 ETENO Y ETANO DE LA FORMULA GENERAL (I), DONDE W, R1, R2, R6A, R6B, R7, R14, R15, R16, R11, R11'', Y R19 TIENEN EL SIGNIFICADO DADO EN LA DESCRIPCION, ASI COMO UN PROCEDIMIENTO PARA SU ELABORACION. LOS NUEVOS COMPUESTOS POSEEN ACTIVIDAD GESTAGENA INTENSA Y SON APROPIADOS PARA LA ELABORACION DE MEDICAMENTOS.
ES93922949T 1992-10-13 1993-10-13 4-estrenos puenteados en 19,11, activos como gestagenos. Expired - Lifetime ES2108298T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4235220A DE4235220A1 (de) 1992-10-13 1992-10-13 Gestagen wirksame 19,11ß-überbrückte 4-Estrene

Publications (1)

Publication Number Publication Date
ES2108298T3 true ES2108298T3 (es) 1997-12-16

Family

ID=6470806

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93922949T Expired - Lifetime ES2108298T3 (es) 1992-10-13 1993-10-13 4-estrenos puenteados en 19,11, activos como gestagenos.

Country Status (25)

Country Link
US (2) US5523298A (es)
EP (1) EP0664811B1 (es)
JP (1) JP3302366B2 (es)
KR (1) KR100341066B1 (es)
CN (1) CN1052238C (es)
AT (1) ATE156837T1 (es)
AU (1) AU677019B2 (es)
BR (1) BR9307232A (es)
CA (1) CA2146962A1 (es)
CZ (1) CZ284187B6 (es)
DE (2) DE4235220A1 (es)
DK (1) DK0664811T3 (es)
ES (1) ES2108298T3 (es)
FI (1) FI951760A0 (es)
GR (1) GR3024940T3 (es)
HU (1) HU223315B1 (es)
IL (1) IL107232A (es)
NO (1) NO305440B1 (es)
NZ (1) NZ256865A (es)
PL (1) PL179764B1 (es)
RU (1) RU2157814C2 (es)
SK (1) SK280991B6 (es)
TW (1) TW341575B (es)
WO (1) WO1994009025A1 (es)
ZA (1) ZA937614B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4235220A1 (de) * 1992-10-13 1994-06-16 Schering Ag Gestagen wirksame 19,11ß-überbrückte 4-Estrene
DE4413185A1 (de) * 1994-04-12 1995-10-19 Schering Ag 11beta,19-überbrückte 13alpha-Alkylsteroide
DE4413184A1 (de) * 1994-04-12 1995-10-19 Schering Ag 10,11-C¶3¶-überbrückte Steroide
US5912006A (en) * 1996-08-28 1999-06-15 Eboc, Inc. Compositions and methods for alleviating discomforting menstrual pain
WO2002054064A2 (en) * 2000-12-28 2002-07-11 Schering Ag Method for screening for progesterone receptor isoform-specific ligands
US20040121304A1 (en) * 2001-12-21 2004-06-24 Ulrike Fuhrmann Method for screening for progesterone receptor isoform-specific ligands and for tissue-selective progesterone receptor ligands
GB0219345D0 (en) * 2002-08-20 2002-09-25 Givaudan Sa Improvements in or relating to organic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3465010A (en) * 1966-11-22 1969-09-02 Searle & Co 17 - (unsaturated hydrocarbon - substituted) 11,13beta - dialkylgon -4 - ene - 3,17beta-diols and esters thereof
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
US5446178A (en) * 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
DE3717169A1 (de) * 1987-05-19 1988-12-01 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3832303A1 (de) * 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide
DE3917274A1 (de) * 1989-05-24 1990-11-29 Schering Ag 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4038128A1 (de) * 1990-11-27 1992-06-04 Schering Ag 8-en-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4235220A1 (de) * 1992-10-13 1994-06-16 Schering Ag Gestagen wirksame 19,11ß-überbrückte 4-Estrene

Also Published As

Publication number Publication date
GR3024940T3 (en) 1998-01-30
JPH08502276A (ja) 1996-03-12
FI951760L (fi) 1995-04-12
HU9501057D0 (en) 1995-06-28
NO951444L (no) 1995-06-13
SK49495A3 (en) 1995-08-09
JP3302366B2 (ja) 2002-07-15
CA2146962A1 (en) 1994-04-28
RU2157814C2 (ru) 2000-10-20
BR9307232A (pt) 1999-08-24
SK280991B6 (sk) 2000-10-09
CN1052238C (zh) 2000-05-10
AU5177493A (en) 1994-05-09
CN1092428A (zh) 1994-09-21
EP0664811B1 (de) 1997-08-13
NO951444D0 (no) 1995-04-12
IL107232A (en) 1998-06-15
US5703066A (en) 1997-12-30
US5523298A (en) 1996-06-04
HU223315B1 (hu) 2004-05-28
WO1994009025A1 (de) 1994-04-28
RU95109891A (ru) 1997-02-10
KR950703576A (ko) 1995-09-20
FI951760A0 (fi) 1995-04-12
PL308349A1 (en) 1995-07-24
AU677019B2 (en) 1997-04-10
CZ91995A3 (en) 1995-09-13
KR100341066B1 (ko) 2002-12-06
NZ256865A (en) 1996-04-26
EP0664811A1 (de) 1995-08-02
ATE156837T1 (de) 1997-08-15
DE4235220A1 (de) 1994-06-16
IL107232A0 (en) 1994-01-25
DE59307133D1 (de) 1997-09-18
ZA937614B (en) 1994-05-23
HUT71523A (en) 1995-12-28
NO305440B1 (no) 1999-05-31
TW341575B (en) 1998-10-01
DK0664811T3 (da) 1998-03-30
CZ284187B6 (cs) 1998-09-16
PL179764B1 (pl) 2000-10-31

Similar Documents

Publication Publication Date Title
ATE355269T1 (de) Phenylalaninderivate
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
ES2084944T3 (es) Amidas terapeuticas.
ES2150989T3 (es) Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.
SG135969A1 (en) Combination of organic compounds
ES2080739T3 (es) Nitro-compuestos insecticidamente activos.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
IL154350A0 (en) New phenylalanine derivatives
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
ES2148476T3 (es) Derivados de azabicicloalcano n-substituidos como neurolepticos asf.
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
ES2116594T3 (es) Ansamicinas biciclicas y su uso como agentes antitumorales.
CY1108110T1 (el) Παραγοντες και μεθοδοι για προστασια, θεραπεια και επιδιορθωση συνδετικου ιστου
BR9503406A (pt) Formulaçoes farmacêuticas adaptadas para inhibir para perda de osso em um ser humano
DE69525354D1 (de) Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
ES2163538T3 (es) Derivados de 3-oxo y 3-tioxo-4-aza-androstano diastereomericamente puros y su uso como antiandrogenos.
ES2107035T3 (es) Derivados de 3-azabiciclo(3.2.0)heptano n-substituidos como neurolepticos etc..
IT1275816B1 (it) Composizioni farmaceutiche solide per uso vaginale
ES2108298T3 (es) 4-estrenos puenteados en 19,11, activos como gestagenos.
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
DE69928646D1 (de) Derivate des streptogramins, ihre herstellung und sie enthaltende zubereitungen
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
ES2082894T3 (es) Dihidropirido(4,3-d)pirimidinas 4-sustituidas como analgesicos y agentes antiinflamatorios topicos para el tratamiento de enfermedades de la piel.
ES2144154T3 (es) Derivados de eritromicina a 9-0-oxima dotados de actividad antibiotica.
CA2427573A1 (en) Indole derivatives as pde5-inhibitors

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 664811

Country of ref document: ES